Diarrhea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Diarrhea - Pipeline Review, H2 2016

Diarrhea - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Diarrhea - Pipeline Review, H2 2016
Published Jul 20, 2016
164 pages — Published Jul 20, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Diarrhea - Pipeline Review, H2 2016, provides an overview of the Diarrhea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diarrhea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diarrhea and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Diarrhea
- The report reviews pipeline therapeutics for Diarrhea by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Diarrhea therapeutics and enlists all their major and minor projects
- The report assesses Diarrhea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Diarrhea

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Diarrhea
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Diarrhea pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying

  
Source:
Document ID
GMDHC8281IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents29
  List of Tables91
  List of Figures101
Introduction111
  Global Markets Direct Report Coverage111
Diarrhea Overview121
Therapeutics Development132
  Pipeline Products for Diarrhea Overview131
  Pipeline Products for Diarrhea Comparative Analysis141
Diarrhea Therapeutics under Development by Companies152
Diarrhea Therapeutics under Investigation by Universities/Institutes171
Diarrhea Pipeline Products Glance183
  Late Stage Products181
  Clinical Stage Products191
  Early Stage Products201
Diarrhea Products under Development by Companies213
Diarrhea Products under Investigation by Universities/Institutes241
Diarrhea Companies Involved in Therapeutics Development2531
  A. Menarini Industrie Farmaceutiche Riunite Srl251
  Ache Laboratorios Farmaceuticos S/A261
  Actelion Ltd271
  Aegis Therapeutics, LLC281
  AlbireoPharma291
  Allergan Plc301
  Anatara Lifesciences Limited311
  Ardelyx, Inc.321
  Assembly Biosciences, Inc.331
  Codagenix, Inc.341
  Cosmo Pharmaceuticals S.p.A351
  DesignMedix, Inc.361
  DiscoveryBiomed, Inc.371
  Genextra S.p.a.381
  GlaxoSmithKline Plc391
  GP Pharm, S.A.401
  Mucosis B.V.411
  Nippon Shinyaku Co., Ltd.421
  Novartis AG431
  Pfizer Inc.441
  Prokarium Limited451
  Protagonist Therapeutics Inc.461
  Rebiotix Inc.471
  Recce Pty Ltd481
  RxBio, Inc.491
  Scandinavian Biopharma Holding AB501
  Sigmoid Pharma Limited511
  Summit Therapeutics Plc521
  Synthetic Biologics, Inc.531
  Syntiron LLC541
  Tasly Pharmaceutical Group Co., Ltd.551
Diarrhea Therapeutics Assessment5611
  Assessment by Monotherapy Products561
  Assessment by Target573
  Assessment by Mechanism of Action603
  Assessment by Route of Administration632
  Assessment by Molecule Type652
Drug Profiles6783
  ABM-101 Drug Profile671
  ACH-04 Drug Profile681
  ASP-7147 Drug Profile691
  cadazolid Drug Profile702
  Campylobacter jejuni [strain CPS81-176] vaccine Drug Profile722
  cholestyramine Drug Profile741
  Clostridium difficile vaccine Drug Profile751
  crofelemer DR Drug Profile763
  Drug for Diarrhea Drug Profile791
  eluxadoline Drug Profile804
  Escherichia coli vaccine Drug Profile841
  ETEC vaccine Drug Profile851
  ETEC vaccine Drug Profile861
  Etvax Drug Profile872
  GVXNSD-133 Drug Profile891
  GXG-8 Drug Profile901
  ibodutant Drug Profile911
  IMSUTMR-1501 Drug Profile921
  infectious diarrhea [serotype H11] vaccine Drug Profile931
  LJN-452 Drug Profile941
  obeticholic acid Drug Profile9511
  octreotide acetate Drug Profile1061
  octreotide acetate MAR Drug Profile1071
  Peptide to Activate NHE-3 for Diarrhea Drug Profile1081
  PF-06425090 Drug Profile1092
  prulifloxacin Drug Profile1112
  PZ-7475 Drug Profile1131
  RBX-2660 Drug Profile1143
  RDX-98940 Drug Profile1171
  RECCE-355 Drug Profile1181
  Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea Drug Profile1191
  Recombinant Proteins for Infectious Diarrhea Drug Profile1201
  ribaxamase Drug Profile1215
  ridinilazole Drug Profile1265
  rifamycin CR Drug Profile1312
  Rx-100 Drug Profile1332
  Small Molecule to Block CFTR for Diarrhoea Drug Profile1351
  Small Molecule to Inhibit EnaC and CFTR for Cystic Fibrosis, Diarrhea and Autosomal Dominant Polycystic Kidney Disease Drug Profile1361
  Small Molecules for Microbial Infections Drug Profile1371
  Small Molecules to Inhibit Beta-Glucuronidase for Chemotherapy Induced Diarrhea Drug Profile1381
  Small Molecules to Inhibit CFTR for Secretory Diarrhea Drug Profile1391
  SYN-006 Drug Profile1401
  SYN-007 Drug Profile1411
  Synthetic Peptide for Irritable Bowel Syndrome with Diarrhea Drug Profile1421
  Typhetec Drug Profile1431
  Vaccine 1 for Diarrhea Drug Profile1441
  Vaccine 2 for Diarrhea Drug Profile1451
  Vaccine for Traveler's Diarrhea Drug Profile1461
  Vaccine for Traveler's Diarrhea Drug Profile1471
  Vaccine to Target Capsular Vi Polysaccharide Antigen for Traveler's Diarrhea Drug Profile1481
  Yersinia pestis vaccine Drug Profile1491
Diarrhea Dormant Projects1503
Diarrhea Discontinued Products1531
Diarrhea Product Development Milestones1549
  Featured News &Press Releases1541
    Jul 07, 2016: Synthetic Biologics Receives USAN Approval for Generic Name Ribaxamase for Phase 2 Drug Candidate SYN-0041541
    Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX1551
    May 16, 2016: Synthetic Biologics Announces Positive Topline Results from Second Phase 2a Clinical Trial of SYN-004 for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea1551
    Mar 07, 2016: Napo and Salix Settle Litigation1561
    Mar 01, 2016: Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the Prevention of C. difficile Infection and Antibiotic-Associated Diarrhea1571
    Dec 14, 2015: Allergan Announces U.S. Availability of VIBERZI (eluxadoline) for Treatment of Irritable Bowel Syndrome with Diarrhea in Adults1571
    Dec 07, 2015: Synthetic Biologics to Webcast on SYN-004 at Microbiome Clinical Program Seminar1581
    Nov 19, 2015: Synthetic Biologics to Host Microbiome Clinical Program Seminar on SYN-004 in New York City1581
    Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix1581
    May 06, 2014: Intercept Reports Additional Positive OCA Data in Patients With Bile Acid Diarrhea at Digestive Disease Week1591
    Feb 27, 2014: Actelion's Novel Antibiotic Cadazolid Receives US FDA Qualified Infectious Disease Product Designation For The Treatment Of Clostridium Difficile-Associated Diarrhea1601
    Feb 25, 2014: Salix Wins Napo Pharmaceuticals Litigation1611
    Jan 14, 2014: Fulyzaq 125 mg Delayed-Release Tablets Significantly Improves Noninfectious Diarrhea in Adult Patients Living with HIV on ART Therapy1612
Appendix1632
  Methodology1631
  Coverage1631
  Secondary Research1631
  Primary Research1631
  Expert Panel Validation1631
  Contact Us1631
  Disclaimer1641

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Diarrhea - Pipeline Review, H2 2016" Jul 20, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diarrhea-Pipeline-Review-H2-2016-2088-16246>
  
APA:
Global Markets Direct - Market Research. (2016). Diarrhea - Pipeline Review, H2 2016 Jul 20, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Diarrhea-Pipeline-Review-H2-2016-2088-16246>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.